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ORIGINAL ARTICLE
Implementation of Basal–Bolus Therapy
in Type 2 Diabetes: A Randomized Controlled Trial
Comparing Bolus Insulin Delivery Using an Insulin Patch
with an Insulin Pen
Richard M. Bergenstal, MD,1 Mark Peyrot, PhD,2 Darlene M. Dreon, DrPH,3 Vanita R. Aroda, MD,4
Timothy S. Bailey, MD,5 Ronald L. Brazg, MD,6 Juan P. Frias, MD,7 Mary L. Johnson, RN, CDE,1
David C. Klonoff, MD,8 Davida F. Kruger, MSN,9 Shenaz Ramtoola, MD,10 Julio Rosenstock, MD,11
Pierre Serusclat, MD,12 Ruth S. Weinstock, MD, PhD,13 Ramachandra G. Naik, MD,3
David M. Shearer, MD,3 Vivien Zraick, MS,3 and Brian L. Levy, MD3;
on behalf of the Calibra Study Group
Abstract
Background: Barriers to mealtime insulin include complexity, fear of injections, and lifestyle interference. This
multicenter, randomized controlled trial evaluated efficacy, safety, and self-reported outcomes in adults with
type 2 diabetes, inadequately controlled on basal insulin, initiating and managing mealtime insulin with a
wearable patch versus an insulin pen.
Methods: Adults with type 2 diabetes (n= 278, age: 59.2– 8.9 years), were randomized to patch (n= 139) versus
pen (n= 139) for 48 weeks, with crossover at week 44. Baseline insulin was divided 1:1 basal: bolus. Using a
pattern-control logbook, subjects adjusted basal and bolus insulin weekly using fasting and premeal glucose targets.
Results: Glycated hemoglobin (HbA1c) change (least squares mean – standard error) from baseline to week 24
(primary endpoint) improved (P< 0.0001) in both arms, -1.7%– 0.1% and -1.6%– 0.1% for patch and pen
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(-18.6– 1.1 and -17.5– 1.1 mmol/mol), and was maintained at 44 weeks. The coefficient of variation of 7-point
self-monitoring blood glucose decreased more (P= 0.02) from baseline to week 44 for patch versus pen. There
were no differences in adverse events, including hypoglycemia (three severe episodes per arm), and changes in
weight and insulin doses. Subject-reported treatment satisfaction, quality of life, experience ratings at week 24,
and device preferences at week 48 significantly favored the patch. Most health care providers preferred patch
for mealtime insulin.
Conclusions: Bolus insulin delivered by patch and pen using an algorithm-based weekly insulin dose titration
significantly improved HbA1c in adults with type 2 diabetes, with improved subject and health care provider
experience and preference for the patch.
Keywords: Mealtime insulin patch, Type 2 diabetes.
Introduction
Type 2 diabetes is a rapidly growing epidemic, chal-lenging health care providers and health care systems to
manage its acute and long-term effects.1,2 Despite an in-
creasing number of treatment options, only about 50% of
people with diabetes on any therapy and <30% of people with
diabetes using some form of insulin therapy achieve the re-
commended treatment goal of glycated hemoglobin (HbA1c)
<7.0% (<53 mmol/mol).3–5 Current guidelines recommend a
stepwise approach to treatment intensification, with a com-
bination of oral and/or injectable antihyperglycemic agents
for people with type 2 diabetes who do not achieve glycemic
goals with lifestyle management and pharmacologic mono-
therapy (typically metformin).
Insulin therapy usually is initiated with a basal formula-
tion, which primarily targets control of fasting plasma glu-
cose. Options for further intensification of injected therapy
include the following: adding rapid-acting mealtime insulin
at the largest meal of the day (a ‘‘basal–plus’’ regimen) and, if
necessary, then adding mealtime insulin doses at other meals
(a ‘‘basal–bolus’’ regimen); adding a glucagon-like peptide
(GLP)-1 receptor agonist; or switching to 2 (and if necessary
3) injections of premixed insulin.3,6–8
The benefits of early insulin intervention for achieving
improved glycemic control are well-established9; however,
initiation of basal insulin often is delayed by up to 7 years or
more.10 Similarly, advancement from basal insulin alone to
mealtime insulin or other combinations (e.g., GLP-1 receptor
agonist therapy) was postponed for an estimated 4.3 years in
one database analysis.11 This reluctance to intensify treat-
ment is referred to as clinical or therapeutic inertia.12 Health
care providers may delay treatment intensification be-
cause they lack the time and resources to adequately educate
the patient and/or they do not have sufficient experience/
expertise to implement more complex insulin treatment
regimens.13–15 Patient barriers to insulin use include fear of
injections, perceived social stigma, interference with daily
activities, reduced quality of life, and increased cost.16–18
Some technological advances to simplify insulin delivery
may address some of the abovementioned barriers. In recent
years, a number of wearable devices have been designed and
developed to deliver basal and/or mealtime insulin.19 One
such device is the insulin patch or simply ‘‘patch’’ (PAQ
MEAL; CeQur, Marlborough, MA, formerly of Calibra
Medical, Wayne, PA), a simplified on-demand subcutaneous
delivery device for mealtime insulin that, unlike conventional
pumps, is entirely mechanical and not managed by external
controllers. Unlike insulin pens, the patch does not require
observation of an injection.
The aim of this study was to compare the efficacy and
safety of the patch with that of a standard insulin pen for
initiating and managing mealtime analog insulin in people
with type 2 diabetes not yet achieving the glycemic goal with
basal insulin with/without other antihyperglycemic agents.
A simple basal–bolus dosing algorithm was implemented.
The study also evaluated subject and health care provider
preferences for patch versus pen.
Research Design and Methods
Study devices
The patch is a small, wearable mechanical pump (65·
35 · 8 mm; 10 g before filling) that can be worn on the body
for up to 3 days for the delivery of mealtime insulin. In the
United States, it is approved for use with rapid-acting insulins
lispro (Humalog; Eli Lilly and Co., Indianapolis, IN) and
aspart (NovoLog/NovoRapid; Novo Nordisk, Inc., Plains-
boro, NJ); aspart was used in the present study. The patch
holds up to 200 units of insulin and delivers a 2-unit dose via a
subcutaneous cannula with each simultaneous depression of
the two buttons on either side of the device. Patients adhere
the patch to a cleaned area (100· 150 mm) on the abdomen.
The patch can be worn under clothing and access to the 2
buttons can be achieved either directly or through clothing
(Fig. 1).20 The comparator device was a NovoLog/NovoRapid
FlexPen (insulin aspart) (Novo Nordisk Pharmaceuticals,
Inc., Princeton, NJ).
Study design
This randomized, multicenter, open-label, parallel, two-
arm interventional study (NCT02542631; EudraCT 2015-
003761-28) compared efficacy, safety, and self-reported
outcomes in adults with type 2 diabetes on basal insulin
therapy who initiated and managed mealtime insulin therapy
with patch versus pen. The study was conducted in accor-
dance with the Declaration of Helsinki (1964), including all
amendments, the International Conference on Harmonization
Good Clinical Practice guidelines, International Organiza-
tion for Standardization regulations, and relevant local laws
and regulations. All subjects provided written informed con-
sent before study participation.
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Study subjects (22–75 years) were recruited from a total of
62 clinical centers in the following countries: the United
States (n = 37), France (n = 9), Germany (n = 6), and the
United Kingdom (n = 10). Inclusion criteria included a clin-
ical diagnosis of type 2 diabetes, treatment with basal insulin
for at least 6 months (with/without antihyperglycemic agents),
with a stable dose [‡0.3 units/(kg$day); £100 units/day]
maintained for at least 6 weeks; HbA1c level of 7.5%–11.0%
(53–97 mmol/mol); willingness to perform self-monitoring of
blood glucose (SMBG); and a body mass index (BMI)
£40 kg/m2. Exclusion criteria included treatment with meal-
time insulin or continuous subcutaneous insulin infusion
within the prior year outside of an acute illness or hospital
setting; two or more severe hypoglycemic episodes within the
prior year; hypoglycemic unawareness; or moderate-to-severe
illness.
Following a 4-week screening and baseline period, sub-
jects were randomized according to study site and study de-
vice (1:1 to patch or pen). They were followed for 44 weeks
to evaluate glycemic control, safety, and treatment experi-
ence. At week 44, subjects crossed over to the other treatment
arm for 4 weeks to evaluate their preferences for patch versus
pen at week 48.
Health care providers completed an experience survey
after the last subject at their site finished week 24 of the study.
Intervention
At randomization, health care providers instructed
all subjects to continue taking basal insulin either before
their evening meal or at bedtime using insulin glargine
(SoloSTAR pen); those using another basal insulin were
switched. Subjects were instructed on the use of their as-
signed device (patch or pen) for mealtime insulin delivery.
Training in the use of the patch included filling the device,
applying it to the skin (lower abdomen), and locating the two
buttons over clothing to activate dosing. Study-site personnel
received patch training and technical support from the study
sponsor (CeQur, formerly of Calibra Medical). Blood glu-
cose meters (Verio IQ) for SMBG were provided by Life-
Scan, Inc. (Wayne, PA).
Concomitant biguanides, alpha-glucosidase inhibitors,
sodium–glucose cotransporter 2 inhibitors, thiazolidinediones,
and dipeptidyl-peptidase 4 inhibitors approved for use with
mealtime insulin were continued at their current doses. Sub-
jects were required to discontinue concomitant sulfonylureas,
meglitinides, bromocriptine, dipeptidyl-peptidase 4 inhibi-
tors, and GLP-1 receptor agonists that were not approved for
use with mealtime insulin. The prestudy, total daily basal
insulin dose was divided 1:1 between basal and mealtime
insulin, that is, half of the total daily insulin dose was given as
basal insulin and half as mealtime insulin (split evenly be-
tween usual daily meals) at randomization. In subjects with
HbA1c <9.0% (<75 mmol/mol) at screening, the daily basal
insulin dose was reduced by 10% before splitting into basal
and mealtime insulins to decrease the potential for hypogly-
cemia. Subjects were instructed on how to adjust their basal
and mealtime insulin doses weekly, using a pattern-based
logbook combining SMBG values with a simple insulin ad-
justment algorithm.21,22 No carbohydrate counting was re-
quired. Background insulin doses were adjusted each week by
adding 2–4 units or subtracting 4 units of glargine insulin from
the current evening basal insulin dose if the weekly fasting
glucose values were either consistently high or low, respec-
tively. Using the usual dose for each week, each mealtime
insulin dose was then corrected using 2-unit increments be-
fore each meal based on premeal SMBG values (simple cor-
rection scale) and meal size (larger or smaller than usual). In
addition, subjects could add an insulin dose of 2 units for
snacks exceeding one carbohydrate serving.
Subjects were asked to perform SMBG every day throughout
the study before morning, midday, and evening meals, at
bedtime, and when hypoglycemia was suspected based on
symptoms. During the baseline period and before study visits
at weeks 4, 12, 24, 36, and 44, subjects recorded in a diary 3
days of 7-point SMBG values (preprandial [3], 2-h post-
prandial [3], and bedtime measurements) along with insulin
doses. They also recorded any adverse events, including
hypoglycemic events, in the diary. Phone calls with subjects
were conducted at weeks 1, 2, 3, 6, and 8 to assist them with
self-titration.
Outcomes
The primary endpoint was change in HbA1c from baseline
to week 24, assessing for noninferiority of the patch to the pen.
Prespecified secondary clinical endpoints included the per-
centage of subjects achieving HbA1c £7.0% (£53 mmol/mol)
FIG. 1. The patch. The wearable, on-demand, mealtime insulin-delivery system patch (Calibra Medical, Wayne, PA)
contains up to 200 units of insulin and measures no more than 65 · 35· 8 mm (A). It can be worn on the abdomen for up to 3
days (B). Mealtime insulin can be dosed in 2-unit increments through clothing by actuating the buttons on both sides of the
patch (C).
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at weeks 24 and 44; change in HbA1c from baseline to week
44; change in fasting plasma glucose from baseline to weeks
24 and 44; change in 3-day average 7-point SMBG values
(mean daily blood glucose [MDBG]), including the coefficient
of variation (CV) of MDBG, calculated from the 7-point
SMBG profile over 3 days (21 values in total) at weeks 24 and
44; and change in 3-day average insulin doses (total daily dose,
basal dose, mealtime dose) from baseline to weeks 24 and 44.
Safety measures included changes in body weight, clini-
cally important changes in laboratory tests or vital signs, ad-
verse events, device-related adverse events, and the frequency
of hypoglycemic events (documented nonsevere symptomatic,
documented nonsevere asymptomatic, and severe hypogly-
cemia). Documented nonsevere symptomatic hypoglycemia
was defined as an event with typical symptoms of hypogly-
cemia accompanied by a measured glucose concentration by
SMBG £70 mg/dL (£3.9 mmol/L). Documented nonsevere
asymptomatic hypoglycemia was defined as an event with
measured glucose £70 mg/dL (£3.9 mmol/L) without symp-
toms. Severe hypoglycemia was defined as an event requiring
the assistance of another person to actively administer car-
bohydrate (including intravenous dextrose), glucagon, or
other resuscitative actions.23 Nocturnal hypoglycemia was
defined as any hypoglycemic event occurring between mid-
night and 6 A.M.
Self-reported outcomes evaluated were insulin regimen
adherence at weeks 24 and 4424,25; subject-experience sur-
veys at week 24 (ease of use, social interference), week 44
(diabetes management), and week 48 (preference for patch
vs. pen) (developed at Calibra Medical); and changes in
treatment satisfaction (Insulin Delivery System Rating Ques-
tionnaire)13 and quality of life (Diabetes Specific Quality of
Life Scale)26 from baseline to week 24. A preference survey
for health care providers regarding use of patch versus pen
(developed by Calibra Medical) was used after the last subject
completed the week 24 visit.
Sample size
Sample size determination was based on the primary
endpoint of HbA1c change from baseline to week 24. As-
suming a true mean difference in change of HbA1c (patch vs.
pen) of -0.1% (standard deviation [SD] 1.2%) (-1.1 [SD
13.1] mmol/mol), 250 completers (125 per arm) were re-
quired to achieve a power of 90% for noninferiority with a
0.4% margin. Allowing for a 20% discontinuation rate by
week 24, the target number of randomized subjects was 312
(156 per arm).
Statistical analyses
Unless otherwise noted, all tests of device effects were
conducted at a two-sided alpha of 0.05, and two-sided con-
fidence intervals (CIs) at 95%. For the primary endpoint,
differences between treatment arms at week 24 were ana-
lyzed using ANCOVA with baseline HbA1c as covariate.
Noninferiority (patch to pen) was concluded from the upper
boundary of the two-sided 95% CI for change in HbA1c from
baseline to week 24 being less than the inferiority margin of
0.4%.27 A modified intent-to-treat analysis set was used and
included all the randomized intent-to-treat subjects who had a
baseline HbA1c and at least one postbaseline HbA1c mea-
surement (n = 274). If week 24 HbA1c measurement was
missing, the last observation carried forward imputation
method was used. Results are shown as mean – standard error
(SE), unless noted otherwise.
Secondary endpoints were tested for superiority, but re-
sults were to be interpreted inferentially only if noninferiority
was demonstrated for the primary endpoint. Continuous
endpoints were analyzed using the ANCOVA model de-
scribed previously. The categorical endpoints were analyzed
using a Cochran–Mantel–Haenszel test, with a type 1 error
rate of 0.05. The change in HbA1c from weeks 24 to 44 was
analyzed using a t-test for each treatment arm.
For analysis of the subject-experience surveys (weeks 24
and 44), a chi-squared test was used for comparisons of the
two arms. For the participant-preference survey (week 48)
and health care provider-experience survey (week 24), a
within-group binomial test P-value was calculated after ex-
cluding neutral answers (Likert scale 3) and tested (Likert
scale 4/5 vs. 1/2) with a null hypothesis probability (Likert
scale 4/5) of 0.5; the hypothesis tested is that there are more
favorable ratings than unfavorable ratings. A chi-squared test
was used for the comparisons of the participant-preference
survey (week 48) in the two crossover groups (patch use for
44 weeks vs. 4 weeks).
Results
Subjects
Baseline characteristics are shown in Table 1. Subjects
(n = 278) were enrolled between July 2015 and August 2016
and were randomized 1:1 to either patch (n = 139) or pen
(n = 139). Of those, 241 (87%) and 216 (78%) completed
week 24 and week 44 assessments, respectively. The study
population was 60% male, with an average age of 59.2 – 8.9
years, mean duration of diabetes 15.0 – 7.5 years, and BMI
32.6 – 4.4 kg/m2. The ethnic distribution of subjects was 89%
Caucasian, 8% African American, 2% Asian, 1% American
Indian, and 1% other. Geographic representation was 78%
from the United States, 12% from France, 8% from the
United Kingdom, and 2% from Germany.
Efficacy outcomes
Primary endpoint. The least squares (LS) mean change
in HbA1c from baseline to week 24 (– SE) was significant
for both arms (-1.7% – 0.1% [-18.5 – 0.9 mmol/mol] and
-1.6% – 0.1% [-17.5 – 0.9 mmol/mol] for patch and pen,
respectively; P < 0.0001) (Table 1 and Fig. 2A); the treatment
arm comparison met the predefined threshold for non-
inferiority of patch versus pen (P < 0.0001). Improvement in
glycemic control was maintained from baseline to week 44
(LS mean change -1.6%– 0.1% [-17.8 – 1.1 mmol/mol] and
-1.6% – 0.1% [-17.8 – 1.1 mmol/mol] for patch and pen,
respectively).
Secondary endpoints. A total of 63% of patch users and
56% of pen users achieved HbA1c £7.0% (£53 mmol/mol) at
week 24 (odds ratio [OR] 1.3, SE 0.25, 95% CI 0.81–2.14;
P = 0.26). The proportions of patch and pen users who
achieved HbA1c £7.0% (£53 mmol/mol) at week 44 rose to
65% and 63%, respectively (OR 1.2, SE 0.28, 95% CI 0.64–
1.93; P= 0.71). The LS mean change (– SE) in fasting plasma
glucose was significant for both patch and pen from baseline
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FIG. 2. Results for glycemic control. (A) HbA1c from baseline to week 44 in patch versus pen users. (B) Fasting plasma
glucose from baseline to week 44 in patch versus pen users. (C) Seven-point SMBG profile at baseline, week 24, and week
44 in patch versus pen users. A significant reduction in SMBG was observed from baseline to weeks 24 and 44 for each of
the seven time points (P< 0.0001) in both treatment arms. HbA1c, glycated hemoglobin; NS, nonsignificant between
treatment arms; SMBG, self-monitoring of blood glucose.
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to week 24 (P < 0.0001) (Table 1 and Fig. 2B). The fasting
glucose target was 71–130 mg/dL and the 24-week fasting
glucose was 136.1– 4.6 and 138.8+ 4.3 mg/dL in the patch
and pen groups, respectively, indicating that there may still
have been room for additional basal insulin adjustment.
A significant decrease in the 7-point SMBG was observed at
weeks 24 and 44 for both patch and pen (P < 0.0001) (Table 1
and Fig. 2C). The CV of the MDBG of 7-point SMBG de-
creased from baseline to week 44 for patch (-1.2%– 0.8%);
in contrast, an increase in 3-day CV of 7-point SMBG was
observed in the pen treatment arm (1.4%– 0.8%). The dif-
ference in change between patch and pen was statistically
significant (-2.6% – 1.1%; 95% CI -4.8 to -0.4; P= 0.022)
(Table 1). Basal and bolus insulin doses, insulin total daily
dose, units/day, and units/kg increased from baseline to
weeks 24 and 44 in both treatment arms, with no significant
difference between the groups (Table 1). Basal:bolus insulin
ratio decreased from 1.1 to 0.8 from baseline to weeks 24 and
44 similarly in both groups (Table 1).
Safety outcomes
Average body weight increased similarly in the two treat-
ment arms by week 24 (patch: 3.9– 0.4 kg; pen: 4.0– 0.4 kg)
and week 44 (patch: 5.1 – 0.5 kg; pen: 5.3 – 0.5 kg), with no
significant difference between groups (Table 1). Similar
percentages of subjects in both treatment arms experienced
hypoglycemic events (Table 1). Three episodes of severe
hypoglycemia per treatment arm were reported (2.2% per
arm) over the 44 weeks (Table 1), three of which were con-
sidered serious adverse events (one in a subject using the
patch and two in subjects using the pen) and related to in-
tensifying insulin therapy. Adverse events at week 44 were
similar between treatment arms (71.9% and 71.2% for patch
vs. pen, respectively). Serious adverse events were reported
in 7.2% and 9.4% of subjects using patch and pen, respec-
tively; most of these (90% and 85%, respectively) were
deemed unrelated to intensifying insulin therapy. Three deaths
occurred—one subject using patch and two subjects using
the pen; these were unrelated to intensifying insulin therapy.
Five subjects discontinued the study because of serious ad-
verse events other than death: three subjects who were using
the patch (angina, coronary artery disease, severe hypoglyce-
mia) and two who were using the pen (bone abscess, severe
hypoglycemia).
At week 48, 9% of subjects (25/278) using the patch re-
ported 33 device-related adverse effects, including bleeding
at the insertion site (7 events); injection-site bruising and
contusion (5 events); insertion-site pain (4 events); injection-
site mass, edema, and vesicles (4 events); insertion-site in-
fection (2 events); discomfort under the tape (injection-site
pruritus, application-site pruritus, injection-site erythema,
injection-site irritation, injection-site rash, miliaria, and
dermatitis) (10 events); and excess sweating under the tape
(1 event). None of the device-related adverse effects was
severe; in fact, the majority were mild in severity. No serious
adverse device-related effects were reported during the study.
Two subjects permanently discontinued the patch during the
study due to adverse device effects of moderate severity (one
injection-site pruritus and one injection-site pain).
The technical performance of the patch device was robust.
Overall, 102 device complaints were reported by 52 patients
(21.1%) through week 44. The most common device com-
plaints included discomfort related to the insertion site
(30 events), button safety (31 events), and product usability
(11 events).
Subject-reported outcomes
Good adherence to mealtime and snack insulin regimens
within the prior 30 days was reported by 79% – 18% and
78% – 16% of subjects using the patch and pen, respectively,
at week 24 (P = 0.68), and 81%– 15% and 81%– 17% of
subjects at week 44, respectively (P= 0.78), with no signifi-
cant differences between treatment arms.
Subject-reported outcomes are shown in Table 2. Changes
in treatment satisfaction with their insulin-delivery system
from baseline to week 24 favored patch over pen for all
measures; comparisons for overall satisfaction and ease-of-
use scores were significant. Changes in quality of life from
baseline to week 24 favored the patch for 6/7 measures;
comparisons of daily functions and diet restrictions were
significant. The scores from the subject-experience survey at
week 24 were positive on all measures for both patch and pen;
participants using the patch recorded significantly higher
ratings compared with those using the pen for 7 of 11 mea-
sures. At week 44, four additional questions about perspec-
tives on diabetes management were asked and both groups
showed similarly positive responses.
The subject-preference survey at week 48 showed that
significantly more subjects preferred the patch to pen for all
measures in those who used the patch for 44 or 4 weeks after
crossover. Most participants stated that they would like to
switch from pen to patch. Longer patch use (44 weeks) was
associated with a significantly higher percentage of subjects
(P = 0.02) wanting to switch from pen to patch when com-
pared with subjects using the patch for 4 weeks.
Health care provider experience
Health care providers (N= 89) gave significant, favorable
ratings for the patch for all measures after 24 weeks (Table 3).
Most health care providers (91.1%, 95% CI 84.8–97.3;
P < 0.0001) preferred the patch to pen to advance subjects
with type 2 diabetes from basal to basal–bolus insulin. In
addition, 89% of health care providers reported that it took
less than 30 min to train subjects on the use of the patch.
Discussion
This study of subjects who previously had not achieved
glycemic goals despite taking moderately high doses of basal
insulin (*0.5 units/kg) with or without other antihyperglycemic
agents showed a substantial and clinically significant decrease
in HbA1c 24 weeks after initiation of mealtime insulin therapy.
This decrease persisted at 44 weeks. A large percentage (83%)
of the decrease in HbA1c was observed after just 12 weeks of
therapy. Within 24 weeks, more than half the subjects in this
study achieved the HbA1c goal of £7.0% (£53 mmol/mol), in-
creasing to about two-thirds of subjects by week 44. There were
no significant differences between treatment arms in measures
of HbA1c or overall mean glucose levels. Subjects in both
treatment arms gained similar amounts of weight. In the study,
any device-related adverse effects were localized to the inser-
tion site and the majority were considered mild in severity. As
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Table 2. Subject-Reported Outcomes
Patch, LS
mean – SE
Pen, LS
mean – SE
Patch vs. pen,
LS mean – SEa
P-value
(patch vs. pen)
Change in insulin-delivery-system treatment satisfaction, baseline to week 24
n = 124 n = 117
Overall satisfactionb -0.7 – 0.1 -0.5 – 0.1 -0.3 – 0.1 <0.01
Satisfaction with ease of usec 13.6– 2.0 4.5 – 2.0 9.2 – 2.8 <0.01
Interference with daily activitiesb 2.5 – 2.2 3.3 – 2.2 -0.8 – 3.1 0.79
Helping with glucose controlc 16.4– 2.0 13.2 – 2.0 3.1 – 2.9 0.27
Worry about glucose controlb -3.3 – 1.6 -0.5 – 1.6 -2.8 – 2.3 0.22
Feelings about yourself and your lifec 3.8 – 1.1 2.5 – 1.1 1.3 – 1.6 0.41
Change in diabetes-specific quality of life, baseline to week 24
n = 124 n = 123
Daily functionsc 2.4 – 1.4 -2.0 – 1.4 4.3 (2.0) 0.03
Diet restrictionsc 6.2 – 1.3 1.9 – 1.3 4.2 (1.8) 0.02
Treatment goalsc 0.9 – 1.0 -0.3 – 1.0 1.1 (1.5) 0.44
Treatment satisfactionb -13.2– 1.4 -11.3 – 1.4 -1.9 (2.0) 0.33
Physical complaintsc 4.5 – 1.3 2.5 – 1.3 2.0 (1.8) 0.26
Emotional burdensc 6.0 – 1.4 3.0 – 1.4 3.0 (1.9) 0.12
Social problemsc 2.5 – 1.1 0.6 – 1.1 1.9 (1.6) 0.22
Patch, %
(95% CI)
Pen, %
(95% CI)
Odds ratio
(95% CI)
P-value
(patch vs. pen)
Subject-experience survey at week 24, % favorablec,d
n = 123 n = 109
Dosed without attracting attention 93.5 (89.8–97.2) 68.8 (61.5–76.1) 6.5 (2.9–14.8) <0.0001
Taking mealtime insulin was painless 90.2 (85.8–94.6) 70.4 (63.1–77.6) 3.9 (1.9–8.0) <0.001
Could do things on the spur of the moment 87.0 (82.0–92.0) 66.7 (59.2–74.1) 3.3 (1.7–6.5) <0.001
Always had mealtime insulin with me 91.2 (86.8–95.5) 72.5 (65.3–79.8) 3.9 (1.8–8.5) <0.001
Felt comfortable using it socially 89.3 (84.7–93.9) 71.0 (63.8–78.2) 3.4 (1.7–7.0) <0.001
Taking mealtime insulin was easy 92.7 (88.8–96.5) 78.0 (71.5–84.5) 3.6 (1.6–8.1) <0.01
Recommend for mealtime insulin 91.0 (86.7–95.2) 78.9 (72.5–85.3) 2.7 (1.2–5.8) 0.01
Better relationship with my health care provider 74.6 (68.1–81.1) 66.1 (58.6–73.5) 1.5 (0.9–2.7) 0.16
Confident that dosed correctly 91.9 (87.8–95.9) 89.9 (85.2–94.7) 1.3 (0.5–3.1) 0.60
Engaged with managing my diabetes 90.1 (85.6–94.6) 88.9 (83.9–93.9) 1.1 (0.5–2.6) 0.77
Made improvements to my diabetes 87.0 (82.0–92.0) 86.2 (80.8–91.7) 1.1 (0.5–2.3) 0.87
Subject-experience survey at week 44, % favorablec,d
n = 113 n = 108
I feel confident with managing my insulin 93.8 (90.1–97.5) 94.4 (90.8–98.1) 0.9 (0.3–2.7) 0.84
I have peace of mind in managing my diabetes
for my future
89.4 (84.6–94.1) 91.7 (87.3–96.0) 0.8 (0.3–1.9) 0.56
Has allowed me to fit diabetes management into
my life
92.9 (89.0–96.9) 89.8 (85.0–94.6) 1.5 (0.6–3.9) 0.41
I am taking positive steps with my diabetes
management
88.5 (83.6–93.4) 92.6 (88.4–96.7) 0.6 (0.2–1.5) 0.30
Used patch for
44 weeks,
% (95% CI)
P
Used patch for
4 weeks,
% (95% CI)
P
Odds ratio
(95% CI)
P-value
(44 weeks vs.
4 weeks)
Subject-preference survey at week 48, % preferc,d
n = 108 n = 106
I am more satisfied using the patch compared
with the pen for mealtime insulin therapy
75.0 (68.1–81.9)
<0.0001
63.2 (55.5–70.9)
<0.0001
1.4 (0.69–3.01) 0.34
I prefer using the patch compared with the pen
for mealtime insulin therapy
72.2 (65.1–79.3)
<0.0001
57.5 (49.7–65.4)
<0.0001
1.5 (0.77–3.10) 0.22
With the patch compared with the pen, I had to
carry fewer diabetes supplies with me
82.2 (76.2–88.3)
<0.0001
82.1 (75.9–88.2)
<0.0001
1.7 (0.65–4.61) 0.27
With the patch compared with the pen, I feel less
constrained with my diabetes management
75.9 (69.2–82.7)
<0.0001
66.0 (58.5–73.6)
<0.0001
1.3 (0.53–3.08) 0.58
With the patch compared with the pen, I feel
more freedom with my diabetes management
77.8 (71.2–84.4)
<0.0001
60.0 (52.6–68.2)
<0.0001
1.6 (0.73–3.60) 0.24
(continued)
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the patch can be worn up to 3 days, the possibility for insertion-
site and adhesion complaints might be expected,28 but was quite
low. Overall, the patch demonstrated a good safety profile, with
no serious adverse device-related events and a similarly low
percentage of study-related adverse events with the patch versus
pen (0.7% vs. 1.5%, respectively).
In this study, systematic insulin intensification using a
simplified dosing algorithm for the subject alongside health
care provider oversight and engagement resulted in high
adherence and good glycemic control in both groups. After
nearly a 1-year follow-up, about two-thirds of the subjects
had reached and maintained the treatment target of HbA1c
£7.0% (£53 mmol/mol). In previous reports, only 30% of
patients with diabetes in the United States on insulin therapy
achieved an HbA1c of £7.0% (£53 mmol/mol).4,5 Moreover,
in our study, there was a statistically significant, although
marginal, reduction in glycemic variability (assessed by
measuring the CV of SMBG measurements on multiple,
7-point SMBG profiles over 3 days) with the patch versus pen
after 44 weeks. The reduction in glycemic variability was not
apparent at week 24. These findings are in alignment with the
results of a smaller feasibility study showing that the patch
reduced glycemic variability compared with mealtime insu-
lin by injection.28 This is despite subjects in both groups
reporting similar adherence and achieving similar daily mean
glucose levels. One hypothesis is that the patch made it easier
to maintain consistent glucose levels throughout the day,
rather than subjects needing to make larger corrective doses
to stabilize glucose levels as the day progressed. For exam-
ple, at week 24, there was a greater reduction for patch versus
pen in mean glucose premidday meal (P = 0.01) and post-
midday meal (P = 0.05). The reduction is possibly due to
greater adherence to either the breakfast or the lunch meal-
time bolus, however, this is a post hoc interpretation that
should be regarded with caution. Nevertheless, lower glucose
variability is associated with increased quality of life29 and
decreased risk of pathophysiologic changes associated with
vascular complications.30–32
Table 2. (Continued)
Used patch for
44 weeks,
% (95% CI)
P
Used patch for
4 weeks,
% (95% CI)
P
Odds ratio
(95% CI)
P-value
(44 weeks vs.
4 weeks)
I would recommend the patch compared with the
pen to other patients who are on mealtime
insulin therapy
71.3 (64.1–78.5)
<0.0001
65.1 (57.5–72.7)
<0.0001
1.4 (0.60–3.34) 0.42
I want to switch from the pen to the patch 69.4 (62.2–76.7)
<0.0001
50.9 (43.0–58.9)
0.02
2.2 (1.15–4.30) 0.02
aLS mean that is greater than 2 SE represents a statistically significant (P < 0.05) change.
bLower score is better.
cHigher score is better.
d’’Favorable’’ and ‘‘Prefer’’ are defined as 4 or 5 on a Likert scale of 1–5, with 1= strongly disagree, 2 = disagree, 3 = neutral, 4 = agree,
5 = strongly agree.
Table 3. Health Care Provider-Experience Survey (N= 89)
Response, % favorable
(95% CI)a,b P
I am satisfied with the patch 85.4 (79.2–91.6) <0.0001
I would prescribe the patch to patients who need bolus insulin 84.1 (77.7–90.5) <0.0001
The patch will help patients overcome barriers to insulin injections (syringe/pen) 80.9 (74.0–87.8) <0.0001
Easy for type 2 diabetes patients using the patch to advance from basal to basal–
bolus insulin
79.8 (72.8–86.8) <0.0001
I would prescribe the patch to MDI patients not at goal 78.4 (71.2–85.6) <0.0001
Training patients to use the patch was easy 74.2 (66.5–81.8) <0.0001
I would initiate type 2 diabetes patients uncontrolled on basal to basal–bolus with
the patch
73.9 (66.2–81.6) <0.0001
I observed positive diabetes management behavior changes with patients using
the patch
70.8 (62.9–78.7) <0.0001
When patients used the patch, they became engaged with their diabetes
management
68.5 (60.4–76.6) <0.0001
I would prescribe the patch for MDI patients at goal 67.0 (58.8–75.3) <0.0001
I prefer the patch to pen to advance type 2 diabetes patients from basal to basal–
bolus insulin
91.1 (84.8–97.3)c <0.0001
The patch will help me transition patients to basal–bolus therapy sooner/faster 87.5 (79.6–95.4)c <0.0001
With the patch, I had a more gratifying relationship with my patients 73.8 (62.7–85.0)c <0.01
a’’Favorable’’ is defined as 4 or 5 on a Likert scale of 1–5 (1= strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, 5 = strongly agree).
bHigher score is better.
cHealth care provider who expressed a preference excluding neutral responses of >20%.
MDI, multiple daily injections.
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Self-reported adherence to basal–bolus insulin therapy was
high in this study, potentially contributing to the observed
improvements in glycemic control and quality of life. Insulin
therapy generally is associated with lower user satisfaction
and quality of life33; however, in this study, advancing to
mealtime insulin therapy led to improvement in several
subject- and provider-reported outcomes. Overall, the patch
was associated with greater device satisfaction, a more positive
experience, and preference for initiating mealtime insulin when
compared with the pen. The quality-of-life improvements in
this study associated with the patch suggest that this device can
address many issues that affect adherence to mealtime insulin
in real-world therapy implementation, including interference
with lifestyle, daily activities, travel, social situations, embar-
rassment, and injection pain.16,17 In addition, these findings
confirm the results of a smaller feasibility study showing that
the patch offered better quality of life and higher device sat-
isfaction compared with mealtime insulin by injection while
providing similar glycemic control and safety.28
Most health care providers reported that the patch was easy
to use, required a short time for subject training, and was
preferred over a pen for initiating mealtime insulin. These
factors, combined with health care provider recognition of
the positive experience of subjects using the patch, might
reduce barriers to providers recommending and implement-
ing mealtime insulin therapy in real-world settings. If clinical
inertia can be reduced, patients may benefit from reduced
exposure to hyperglycemia, which is likely to reduce the risk
of diabetes complications.34
The strengths of this study include participation by 62 centers
from 4 countries, a randomized design with a comparator arm,
treatment crossover to permit direct comparison of subject
preference, a formal protocol for insulin adjustment/titration,
long duration (48 weeks), and a high rate of retention (78% of
subjects completed week 44 assessments). A limitation was
that it was not possible to blind subjects or health care providers
to the device used, leading to potential expectation effects. This
is a common limitation in studies for medical devices.
Conclusions
This study demonstrated clinically significant improve-
ments in glycemic control after the addition of mealtime
insulin to a basal insulin regimen using either the patch or an
insulin pen. The simplified dosing algorithm was safe and
effective, enabling two-thirds of subjects to reach an HbA1c
£7.0% (£53 mmol/mol). Similar increases in body weight
and low numbers of severe hypoglycemic events were ob-
served in the two treatment arms. Glycemic variability was
marginally reduced for subjects using the patch compared
with the pen. Overall, subjects and health care providers
preferred the patch over the pen for implementing basal–
bolus insulin therapy. The patch can contribute to safely
achieving glycemic control for people initiating basal–bolus
insulin therapy. It can potentially reduce patient and provider
resistance to initiating mealtime insulin therapy and improve
patient adherence and persistence, resulting in improved
glycemic control over time.
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